Extract

The principal objective of the trial is to investigate the antitumor activity of regorafenib in terms of progression Free Survival (PFS) according to modified RECIST (RECIST 1.1) after central radiological review.

Inclusion criteria

• Metastatic bone sarcomas: conventional high grade osteosarcoma, Ewing sarcoma of bone, intermediate or high-grade chondrosarcomas

Links

• ictrp
• euctr